Publications related to Combination therapy

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Jeffrey Alan Hubbell, Melody Swartz, Seung Tae Lee, Lambert Charles François Potin, Jun Ishihara, Kazuto Fukunaga, Michal Mateusz Raczy

Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we addressed ...

AMER ASSOC ADVANCEMENT SCIENCE2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis

Stewart Cole, Anthony Vocat, Jérémie Piton, Shi-Yan Caroline Foo, Andréanne Lupien

Macozinone (MCZ) is a tuberculosis (TB) drug candidate that specifically targets the essential flavoenzyme DprE1, thereby blocking synthesis of the cell wall precursor decaprenyl phosphoarabinose (DPA) and provoking lysis of Mycobacterium tuberculosis. As ...

AMER SOC MICROBIOLOGY2018

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)

Stewart Cole, Anthony Vocat, Shi-Yan Caroline Foo, Andréanne Lupien, Jean-Yves Gillon

The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin, pyrazinamide, and ethambutol) for the treatment of tuberculosis (TB) is menaced by the emergence of multidrug-resistant (MDR) and extensively drugresistant (XDR) strains of ...

AMER SOC MICROBIOLOGY2018

Drug Combination for Treatment of Proliferative Diseases

Paul Joseph Dyson, Hubert van den Bergh, Patrycja Nowak-Sliwinska

Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C c ...

2017

TUCUXI: TUCUXI: An Intelligent System for Personalized Medicine from Individualization of Treatments to Research Databases and Back

Karl Aberer, Yann Thoma, Michael Ignaz Schumacher, Thierry Buclin, Alevtina Dubovitskaya

Therapeutic Drug Monitoring (TDM) is a key concept in precision medicine. The goal of TDM is to avoid therapeutic failure or toxic effects of a drug due to insufficient or excessive circulating concentration exposure related to between-patient variability ...

2017

Optimization of drug combinations using Feedback System Control

Paul Joseph Dyson, Hubert van den Bergh, Patrycja Nowak-Sliwinska

We describe a protocol for the discovery of synergistic drug combinations for the treatment of disease. Synergistic drug combinations lead to the use of drugs at lower doses, which reduces side effects and can potentially lead to reduced drug resistance, w ...

Nature Publishing Group2016

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Paul Joseph Dyson, Hubert van den Bergh, Patrycja Nowak-Sliwinska

Drug combinations can improve angiostatic cancer treatment efficacy and enable the reduction of side effects and drug resistance. Combining drugs is non-trivial due to the high number of possibilities. We applied a feedback system control (FSC) technique w ...

2015

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Combination therapy

Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia

Repurposed drug combination via high-throughput screening and dual drug delivery system development for the treatment of retinoblastoma

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)

Drug Combination for Treatment of Proliferative Diseases

TUCUXI: TUCUXI: An Intelligent System for Personalized Medicine from Individualization of Treatments to Research Databases and Back

Optimization of drug combinations using Feedback System Control

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Graph Chatbot

Chat with Graph Search

Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Repurposed drug combination via high-throughput screening and dual drug delivery system development for the treatment of retinoblastoma

TUCUXI: TUCUXI: An Intelligent System for Personalized Medicine from Individualization of Treatments to Research Databases and Back

Drug Combination for Treatment of Proliferative Diseases

Optimization of drug combinations using Feedback System Control

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)